Newron Pharmaceuticals
NWRN.SW
#8289
Rank
ยฃ0.13 B
Marketcap
ยฃ7.16
Share price
-0.74%
Change (1 day)
75.90%
Change (1 year)

P/E ratio for Newron Pharmaceuticals (NWRN.SW)

P/E ratio at the end of 2023: -5.11

According to Newron Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.33898. At the end of 2023 the company had a P/E ratio of -5.11.

P/E ratio history for Newron Pharmaceuticals from 2006 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2023-5.11213.01%
2022-1.63-17.08%
2021-1.979.7%
2020-1.79-70.49%
2019-6.08-17.14%
2018-7.33-81.39%
2017-39.478.84%
2016-22.029.54%
2015-17.0-52.94%
2014-36.134.67%
2013-26.8-4.98%
2012-28.3991.08%
2011-2.5935.87%
2010-1.91-65.93%
2009-5.59-5.3%
2008-5.91-82.59%
2007-33.9102.9%
2006-16.7

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.